These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 25268885)

  • 1. Detection of colorectal cancer (CRC) by urinary volatile organic compound analysis.
    Arasaradnam RP; McFarlane MJ; Ryan-Fisher C; Westenbrink E; Hodges P; Thomas MG; Chambers S; O'Connell N; Bailey C; Harmston C; Nwokolo CU; Bardhan KD; Covington JA
    PLoS One; 2014; 9(9):e108750. PubMed ID: 25268885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Colorectal cancer and adenoma screening using urinary volatile organic compound (VOC) detection: early results from a single-centre bowel screening population (UK BCSP).
    Mozdiak E; Wicaksono AN; Covington JA; Arasaradnam RP
    Tech Coloproctol; 2019 Apr; 23(4):343-351. PubMed ID: 30989415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary volatile organic compounds and faecal microbiome profiles in colorectal cancer.
    McFarlane M; Millard A; Hall H; Savage R; Constantinidou C; Arasaradnam R; Nwokolo C
    Colorectal Dis; 2019 Nov; 21(11):1259-1269. PubMed ID: 31282600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk stratification of symptomatic patients suspected of colorectal cancer using faecal and urinary markers.
    Widlak MM; Neal M; Daulton E; Thomas CL; Tomkins C; Singh B; Harmston C; Wicaksono A; Evans C; Smith S; Savage RS; Covington JA; Arasaradnam RP
    Colorectal Dis; 2018 Dec; 20(12):O335-O342. PubMed ID: 30248228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of Pancreatic Cancer by Urine Volatile Organic Compound Analysis.
    Nissinen SI; Roine A; Hokkinen L; Karjalainen M; Venäläinen M; Helminen H; Niemi R; Lehtimäki T; Rantanen T; Oksala N
    Anticancer Res; 2019 Jan; 39(1):73-79. PubMed ID: 30591442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-Invasive Diagnosis of Diabetes by Volatile Organic Compounds in Urine Using FAIMS and Fox4000 Electronic Nose.
    Esfahani S; Wicaksono A; Mozdiak E; Arasaradnam RP; Covington JA
    Biosensors (Basel); 2018 Dec; 8(4):. PubMed ID: 30513787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-invasive exhaled volatile organic biomarker analysis to detect inflammatory bowel disease (IBD).
    Arasaradnam RP; McFarlane M; Daulton E; Skinner J; O'Connell N; Wurie S; Chambers S; Nwokolo C; Bardhan K; Savage R; Covington J
    Dig Liver Dis; 2016 Feb; 48(2):148-53. PubMed ID: 26682719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GC-MS metabolomics-based approach for the identification of a potential VOC-biomarker panel in the urine of renal cell carcinoma patients.
    Monteiro M; Moreira N; Pinto J; Pires-Luís AS; Henrique R; Jerónimo C; Bastos ML; Gil AM; Carvalho M; Guedes de Pinho P
    J Cell Mol Med; 2017 Sep; 21(9):2092-2105. PubMed ID: 28378454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urine as a biological modality for colorectal cancer detection.
    Chandrapalan S; Arasaradnam RP
    Expert Rev Mol Diagn; 2020 May; 20(5):489-496. PubMed ID: 32130868
    [No Abstract]   [Full Text] [Related]  

  • 10. Urinary volatile organic compounds for colorectal cancer screening: A systematic review and meta-analysis.
    van Liere ELSA; van Dijk LJ; Bosch S; Vermeulen L; Heymans MW; Burchell GL; de Meij TGJ; Ramsoekh D; de Boer NKH
    Eur J Cancer; 2023 Jun; 186():69-82. PubMed ID: 37030079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differentiating coeliac disease from irritable bowel syndrome by urinary volatile organic compound analysis--a pilot study.
    Arasaradnam RP; Westenbrink E; McFarlane MJ; Harbord R; Chambers S; O'Connell N; Bailey C; Nwokolo CU; Bardhan KD; Savage R; Covington JA
    PLoS One; 2014; 9(10):e107312. PubMed ID: 25330367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Faecal Volatile Organic Compounds to Detect Colorectal Neoplasia in Lynch Syndrome-A Prospective Longitudinal Multicentre Study.
    van Liere ELSA; Ramsoekh D; Daulton E; Dakkak M; van Lingen JM; Stewart TK; Bosch S; Carvalho B; Dekker E; Jacobs MAJM; Koornstra JJ; Kuijvenhoven JP; van Leerdam ME; de Meij TGJ; Meijer GA; Spaander MCW; Covington JA; de Boer NKH
    Aliment Pharmacol Ther; 2025 Jan; 61(1):145-158. PubMed ID: 39422092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urinary volatile organic compound markers and colorectal anastomotic leakage.
    Plat VD; Bootsma BT; Neal M; Nielsen K; Sonneveld DJA; Tersteeg JJC; Crolla RMPH; van Dam DA; Cense HA; Stockmann HBAC; Covington JA; de Meij TGJ; Tuynman JB; de Boer NKH; Daams F
    Colorectal Dis; 2019 Nov; 21(11):1249-1258. PubMed ID: 31207011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel tool for noninvasive diagnosis and tracking of patients with inflammatory bowel disease.
    Arasaradnam RP; Ouaret N; Thomas MG; Quraishi N; Heatherington E; Nwokolo CU; Bardhan KD; Covington JA
    Inflamm Bowel Dis; 2013 Apr; 19(5):999-1003. PubMed ID: 23478806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Electronic nose can discriminate colorectal carcinoma and advanced adenomas by fecal volatile biomarker analysis: proof of principle study.
    de Meij TG; Larbi IB; van der Schee MP; Lentferink YE; Paff T; Terhaar Sive Droste JS; Mulder CJ; van Bodegraven AA; de Boer NK
    Int J Cancer; 2014 Mar; 134(5):1132-8. PubMed ID: 23959518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FAIMS analysis of urine gaseous headspace is capable of differentiating ovarian cancer.
    Niemi RJ; Roine AN; Eräviita E; Kumpulainen PS; Mäenpää JU; Oksala N
    Gynecol Oncol; 2018 Dec; 151(3):519-524. PubMed ID: 30257785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fecal volatile organic compounds for early detection of colorectal cancer: where are we now?
    Bosch S; Berkhout DJ; Ben Larbi I; de Meij TG; de Boer NK
    J Cancer Res Clin Oncol; 2019 Jan; 145(1):223-234. PubMed ID: 30554400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Faecal volatile organic compounds analysis using field asymmetric ion mobility spectrometry: non-invasive diagnostics in paediatric inflammatory bowel disease.
    van Gaal N; Lakenman R; Covington J; Savage R; de Groot E; Bomers M; Benninga M; Mulder C; de Boer N; de Meij T
    J Breath Res; 2017 Nov; 12(1):016006. PubMed ID: 28439048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation of urinary volatile organic metabolites as potential cancer biomarkers by solid-phase microextraction in combination with gas chromatography-mass spectrometry.
    Silva CL; Passos M; Câmara JS
    Br J Cancer; 2011 Dec; 105(12):1894-904. PubMed ID: 22085842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fecal occult blood test for colorectal cancer screening: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2009; 9(10):1-40. PubMed ID: 23074514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.